cream-line
cream-line refers to non-homogenized fluid milk?
cream-line
cream-line refers to non-homogenized fluid milk?
(highland Papua New Guinea tribes, uncontacted Amazonian communities, Sentinelese, interior Maasai/Mongolian herders/Bedouin still on traditional raw dairy only)
cut
Layer 2
In this section we dont discuss what is the smallest sizes in homo and non-homo milk. is that known?
Egg-yolk LDL particles (~25–70 nm) do not challenge this framing
we mentioned egg-yolk earlier, maybe this instance is enough?
childhood exposure onset at age 5–10
how did we conclude this very specific age range?
industrial
drop "industrial", doesnt matter if you do it at home.
Analysed in aggregate, dairy shows no association: total dairy was null in the Ausimmune case-control (Dieu 2022, PMID 35645978) and total dairy was null in a UK MS-register analysis of disease activity (Temperley 2023, PMID 38130338
repetition with slightly different meaning
The signal appears only when milk form is stratified; aggregate-dairy measures yield inconsistent signals across cohorts (null in Ausimmune, protective in three Iranian case-controls, elevated in Sepčić Croatia) consistent with the weighted form-mix in each population
Repeated below
established mechanistic explanation
isnt fermented diary accepted to beneficial? although nothing negative is known about fluid milk right.
No raw-milk recommendation; no "return-to-nature" framing.
Make this paragraph shorter
ms-utredning.pages.dev
This is private, delete
Publishing strategy
Make this section more terse
Author context (determines optimal strategy). No institutional affiliation, no career or funding dependency, no active need to establish publication priority against parallel work. Goal 1 (per CLAUDE.md) is patient-directed evidence; Goal 2 is publishable hypothesis paper as a "nice to have." Strategy is calibrated to this profile — specifically NOT optimized for impact factor, career metrics, or priority racing.
Delete
Iron supplementation not keeping pace — escalate urgently
no iron supplements before, they started day after last blood test.
If fenebrutinib is not yet available, should ocrelizumab/rituximab be reconsidered as a bridge? (Previously declined, Sep 2025)
why are we asking this question? we dont think this is a good idea right? and the doctor didnt think so before either.
Phase 2 showed 30% disability worsening reduction in PPMS subgroup (n=152),
missing link to paper here